Rachna Khosla - 02 May 2022 Form 4 Insider Report for AMGEN INC (AMGN)

Role: SVP, Business Development
Signature: /s/ Rachna Khosla
Issuer symbol: AMGN
Transactions as of: 02 May 2022
Net transactions value: -$12,239
Form type: 4
Filing time: 04 May 2022, 20:00:21 UTC
Previous filing: 29 Apr 2022
Next filing: 09 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMGN	Common Stock	Award	$0	+606	+8.9%	$0.000000	7,434	02 May 2022	Direct	F1
transaction	AMGN	Common Stock	Tax liability	$12,239	-53	-0.71%	$230.92	7,381	03 May 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMGN	Nqso (Right to Buy)	Award	$0	+4,949		$0.000000	4,949	02 May 2022	Common Stock	4,949	$230.92	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.
F2	These shares include the following RSUs granted under the Company's equity plans: 554 RSUs which will vest on 7/31/2022; 142 RSUs which vest in one installment of 142 on 5/3/2023; 300 RSUs which will vest in two installments of 99 on 5/5/2022 and 5/5/2023 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3	These shares include 145 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4	These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.